アシネトバクターバウマンニワクチン:世界の市場機会分析・予測

◆英語タイトル:MarketVIEW: Acinetobacter baumannii vaccines - Acinetobacter baumannii vaccines: global market forecast and size
◆商品コード:VAZ2006012
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2019年5月
◆ページ数:n/a
◆レポート言語:英語
◆レポート形式:Executive presentation (~97 slides .pdf) + 1 MS Excel
workbook (.xls)
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Region PriceUSD8,995 ⇒換算¥935,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
VacZine Analytics社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Acinetobacter baumannii (AB) of the Acinetobacter spp is a ubiquitous aerobic Gram-negative bacillus which preferentially colonises aquatic environments. Because of its high propensity for antimicrobial resistance, the bacterium has become a WHO “Priority No 1” pathogen and poses a critical threat to global human health. AB is associated with around ~1-2% of hospital-acquired infections (HAIs) where colonization is associated with an increased risk of hospital death. Patients usually affected are the critically ill and/or immune-compromised, having been admitted to the intensive care unit (ICU) and often receiving mechanical ventilation. In these instances, AB pneumonia can have high mortality rates (>50%) and importantly, infections can be challenging to treat with current antibiotics especially multidrug-resistant forms MDR, XDR and PDR. AB resistant infections dramatically increase hospital length of stay (LOS) and economic cost.
There are many drivers to justify the search for new management techniques to A.baumannii infections especially immunologic approaches such as prophylatic vaccines and monoclonal antibodies. Several companies have an ongoing preclinical interest such as ALOPEXX, Vaxdyn and Aridis Pharmaceuticals and larger manufacturers would be well advised to be involved. Acinetobacter baumannii is a unique concern, and it is not prudent to evaluate AB alongside high volume comparators that also have an antimicrobial resistance threat.

This MarketVIEW product is composed of a comprehensive Executive summary presentation (~100 slides, .pdf) + MS Excel-based model which forecasts the potential commercial value of a putative Acinetobacter baumannii vaccine across major Western markets to 2030. Three deployment scenarios (LO, BASE and HI) are included based upon successive targeting of patient groups (and specific subsets) who would benefit from vaccination. A detailed review of disease background and epidemiology is included along with current treatment, unmet needs and rationale for vaccine approach. An ideal Target Product Profile (TPP) is defined along with commercial model assumptions with economic pricing justification. This analysis is ideally suited to any organisation wishing to understand and justify investment into this highly important opportunity.

THIS PRODUCT IS A SUMMARY PRESENTATION (.pdf, 100 slides) + 1 MODEL (.xls, 55 worksheets)

To order please contact your region account manager, buy “on-line” or order direct at: orders@vaczine-analytics.com

【レポートの目次】

PRODUCT CONTENTS:
Published May 2019 (CAT No: VAMV070)
****This product is a summary presentation (.pdf), a forecast model (.xls)
Contents – Summary presentation (.pdf)2
Contents
Author’s notes
Executive summary
[SECTION 1] Acinetobacter baumannii vaccines: key commercial model outputs
[SECTION 2] Acinetobacter baumannii: disease background
[SECTION 3] Acinetobacter baumannii: disease epidemiology (global)
[SECTION 4] Acinetobacter baumannii: current treatment and management
[SECTION 5] Acinetobacter baumannii: R&D summary and rationale for vaccine development
[SECTION 6] Acinetobacter baumannii: modelling vaccine commercial potential
Bibliography
Disclaimer
PAGES: ~100 slides fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)
Worksheets = >50 interconnected



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アシネトバクターバウマンニワクチン:世界の市場機会分析・予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆